🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against drug-resistant strains of the infection, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are escalating globally, with figures suggesting over 82 million infections per year. Notably increased rates are observed in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance found that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in recent days for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the drug firm its industry partner to see it through.

“This authorization represents a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Global Access

Based on findings released by a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This places it at an equal footing with the current standard treatment, which uses two antibiotics. The trial enrolled over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the authority to make available and distribute the drug in numerous regions with limited resources.

Medical professionals directly involved have shared optimism. The availability of a easy-to-administer therapy like this is hailed as a "game-changer" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the disease for people and to prevent the spread of untreatable gonorrhoea around the world.